WZ811 (CAS 55778-02-4)
QUICK LINKS
WZ811 is a chemical that functions as a potent and selective inhibitor of the protein tyrosine phosphatase 1B (PTP1B). It acts by binding to the active site of PTP1B, preventing its enzymatic activity and thereby regulating cellular signaling pathways. By inhibiting PTP1B, WZ811 can modulate insulin and leptin signaling, making it useful for studying the molecular mechanisms underlying metabolic disorders and obesity. WZ811 exhibits anti-inflammatory properties by targeting PTP1B-mediated signaling pathways in immune cells. This chemical′s mode of action involves disrupting the dephosphorylation of specific substrates, leading to downstream effects on cellular processes such as glucose metabolism and immune response. In a research and development setting, WZ811′s ability to selectively inhibit PTP1B makes it a useful compound for investigating the role of this phosphatase in various physiological and pathological conditions.
WZ811 (CAS 55778-02-4) References
- Discovery of small molecule CXCR4 antagonists. | Zhan, W., et al. 2007. J Med Chem. 50: 5655-64. PMID: 17958344
- Dipyrimidine amines: a novel class of chemokine receptor type 4 antagonists with high specificity. | Zhu, A., et al. 2010. J Med Chem. 53: 8556-68. PMID: 21105715
- DJ-1 protein regulates CD3+ T cell migration via overexpression of CXCR4 receptor. | Jung, SH., et al. 2014. Atherosclerosis. 235: 503-9. PMID: 24953490
- Synthesis and evaluation of 2,5 and 2,6 pyridine-based CXCR4 inhibitors. | Gaines, T., et al. 2016. Bioorg Med Chem. 24: 5052-5060. PMID: 27576294
- Suppression of chronic lymphocytic leukemia progression by CXCR4 inhibitor WZ811. | Li, SH., et al. 2016. Am J Transl Res. 8: 3812-3821. PMID: 27725861
- Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors. | Dragoj, M., et al. 2017. Invest New Drugs. 35: 718-732. PMID: 28733702
- Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma. | Xu, ZZ., et al. 2018. Leuk Lymphoma. 59: 1451-1460. PMID: 28952842
- CXCR4/CXCR7/CXCL12 axis promotes an invasive phenotype in medullary thyroid carcinoma. | Werner, TA., et al. 2017. Br J Cancer. 117: 1837-1845. PMID: 29112684
- CXCR4/CXCR7/CXCL12-Axis in Follicular Thyroid Carcinoma. | Werner, TA., et al. 2018. J Cancer. 9: 929-940. PMID: 29581772
- Synthesis and evaluation of 2,5-furan, 2,5-thiophene and 3,4-thiophene-based derivatives as CXCR4 inhibitors. | Gaines, T., et al. 2019. Eur J Med Chem. 181: 111562. PMID: 31377592
- Long noncoding RNA FER1L4 suppresses proliferation, invasion, migration and lymphatic metastasis of gastric cancer cells through inhibiting the Hippo-YAP signaling pathway. | Xu, J., et al. 2020. Am J Transl Res. 12: 5481-5495. PMID: 33042432
- MSX-122: Is an effective small molecule CXCR4 antagonist in cancer therapy? | Ghasemi, K. and Ghasemi, K. 2022. Int Immunopharmacol. 108: 108863. PMID: 35623288
- Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics. | Zhang, YA., et al. 2022. Dis Markers. 2022: 3276925. PMID: 35774848
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
WZ811, 1 mg | sc-296701 | 1 mg | $29.00 | |||
WZ811, 5 mg | sc-296701A | 5 mg | $66.00 |